Shares of Vivus (VVUS) were up 1.5% in early trading Friday, after being up nearly 6%, after a study indicated its obesity drug Qsymia reduced certain risk factors for heart disease. The study, whose abstract is available online, indicated that patients who took Qsymia for over a year showed improved blood pressure, cholesterol and triglyceride levels, in addition to significant weight loss. All of these are risk factors for cardiovascular